Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANT-1207 · 1 trial · 1 indication
The HDSS is a patient completed scale that measures how excessive sweating effects quality of life using a 4-point scale where: 1=My underarm sweating is not noticeable and never interferes with my daily activities to 4= My underarm sweating is intolerable and always interferes with my daily activities. GSP was measured using a pre-weighed filter paper placed into the axilla area (armpit) to collect sweat over a 5-minute period. The paper was removed and weighed to determine the amount of sweat produced. The HDSS and the GSP were assessed at Baseline and Week 12. The change from Baseline was calculated. The percentage of participants who had both a change (reduction) from Baseline in HDSS score by ≥ 2 points and a change (reduction) from Baseline in GSP by ≥ 50% is reported.
| Arm | Type | Description |
|---|---|---|
| Vehicle | PLACEBO_COMPARATOR | Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| ANT-1207 Dose 1 | EXPERIMENTAL | Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| ANT-1207 Dose 2 | EXPERIMENTAL | Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| ANT-1207 Dose 3 | EXPERIMENTAL | Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| ANT-1207 Dose 4 | EXPERIMENTAL | Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| ANT-1207 Dose 5 | EXPERIMENTAL | Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0. |
| Name | Type | Description |
|---|---|---|
| Vehicle | BIOLOGICAL | Vehicle for ANT-1207 liniment formulation without active ingredient. |
| ANT-1207 | BIOLOGICAL | Botulinum toxin Type A topical liniment (ANT-1207). |
Inclusion Criteria: * ages 18 - 70 years of age * diagnosis of primary axillary hyperhidrosis * HDSS score of ≥3 * threshold sweat production/axilla in 5 minutes as measured gravimetrically * willingness to shave underarms prior to each study visit Exclusion Criteria: * botulinum toxin treatment ...
ANT-1207 is an investigational monoclonal antibody being developed for hyperhidrosis, a condition of excessive sweating. It is specifically being studied for primary axillary hyperhidrosis, which involves excessive underarm sweating.
ANT-1207 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being studied for its potential to treat hyperhidrosis, though the exact mechanism of action is not publicly detailed.
ANT-1207 is being developed by AbbVie Inc. (NYSE: ABBV), a biopharmaceutical company. The drug is currently in clinical development for hyperhidrosis.
ANT-1207 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
ANT-1207 has one completed Phase 2 clinical trial, identified as NCT02479139, which evaluated the drug in participants with primary axillary hyperhidrosis. The trial enrolled 145 participants in the United States and was randomized, double-blind, and placebo-controlled.
No alternative names for ANT-1207 have been disclosed. It is identified solely by its code name ANT-1207 in clinical development.